-
1“.... Trastuzumab resistance cause relapse of the tumor or dosing mass anti-cancer drug is a major obstacle...”
Get full text
Others -
2by Sy, Jonathan Tiu“... and antigen binding specificity. Trastuzumab, a monoclonal antibody that targets the HER2 receptor, has been...”
Published 2010
Get full text
-
3by Sy, Jonathan Tiu“... and antigen binding specificity. Trastuzumab, a monoclonal antibody that targets the HER2 receptor, has been...”
Published 2010
Get full text
-
4by Balachandran, Banujan“...-bound receptor tyrosine kinase upstream of crucial proliferation and cell survival pathways. Trastuzumab...”
Published 2013
Get full text
Others -
5by Triulzi, Tiziana“...Despite the clinical benefit of trastuzumab, some patients do not respond to this therapy. Aims...”
Published 2017
Get full text
-
6by Sy, Jonathan Tiu“... and antigen binding specificity. Trastuzumab, a monoclonal antibody that targets the HER2 receptor, has been...”
Published 2010
Get full text
-
7“... of trastuzumab in the Asian population is limited. This thesis is thus aimed to describe the prescribing pattern...”
Get full text
Others -
8
-
9
-
10by Walker, Jonathan Robert“...Background: In breast cancer patients, the administration of Trastuzumab and Doxorubicin...”
Published 2010
Get full text
-
11by Walker, Jonathan Robert“...Background: In breast cancer patients, the administration of Trastuzumab and Doxorubicin...”
Published 2010
Get full text
-
12by Sundfors, Anu-Johanna“...-positive breast cancer after progression in trastuzumab-based 1stline treatment. When T-DM1 became...”
Published 2019
Get full text
Others -
13
-
14
-
15
-
16by Mason, Julie“... with two doses of a primary anti-HER2 therapy, trastuzumab (TRAS), in athymic mice. FO alone had no effect...”
Published 2010
Get full text
-
17by Mason, Julie“... with two doses of a primary anti-HER2 therapy, trastuzumab (TRAS), in athymic mice. FO alone had no effect...”
Published 2010
Get full text
-
18
-
19by Thunborg, Emilia“... In this retrospectivecohort study, the aim was to identifythe rate of exceptional respondersto trastuzumab-based therapyand...”
Published 2019
Get full text
Others -
20